Drug · CHEMBL681

ETOMIDATE

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. ETOMIDATE. Drugs and targets, record CHEMBL681. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL681

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: ETOMIDATE; ChEMBL
ChEMBL ID: CHEMBL681; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Amidate; ChEMBL
Other names: Etomidato, Hypnomidate, NSC-759160; ChEMBL
DrugBank: DB00292; DrugBank
InChIKey: NPUKDXXFDDZOKR-LLVKDONJSA-N; ChEMBL
Open Targets' highest stage: Approval, as Open Targets' drug record gives it; Open Targets

Targets16

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
GABRA1	GABA-A receptor; anion channel	GABA-A receptor; anion channel positive modulator	POSITIVE MODULATOR	https://conductscience.org/library/genes/2554
GABRA2	GABA-A receptor; anion channel	GABA-A receptor; anion channel positive modulator	POSITIVE MODULATOR	https://conductscience.org/library/genes/2555
GABRA3	GABA-A receptor; anion channel	GABA-A receptor; anion channel positive modulator	POSITIVE MODULATOR	https://conductscience.org/library/genes/2556
GABRA4	GABA-A receptor; anion channel	GABA-A receptor; anion channel positive modulator	POSITIVE MODULATOR	https://conductscience.org/library/genes/2557
GABRA5	GABA-A receptor; anion channel	GABA-A receptor; anion channel positive modulator	POSITIVE MODULATOR	https://conductscience.org/library/genes/2558
GABRA6	GABA-A receptor; anion channel	GABA-A receptor; anion channel positive modulator	POSITIVE MODULATOR	https://conductscience.org/library/genes/2559
GABRB1	GABA-A receptor; anion channel	GABA-A receptor; anion channel positive modulator	POSITIVE MODULATOR	https://conductscience.org/library/genes/2560
GABRB2	GABA-A receptor; anion channel	GABA-A receptor; anion channel positive modulator	POSITIVE MODULATOR	https://conductscience.org/library/genes/2561
GABRB3	GABA-A receptor; anion channel	GABA-A receptor; anion channel positive modulator	POSITIVE MODULATOR	https://conductscience.org/library/genes/2562
GABRD	GABA-A receptor; anion channel	GABA-A receptor; anion channel positive modulator	POSITIVE MODULATOR	https://conductscience.org/library/genes/2563

1 to 10 of 16Source ChEMBL

See all 16 targets

Diseases16

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
injury	Unknown	ClinicalTrials.gov	3	3	https://conductscience.org/library/drugs?q=MONDO_0021178
Sepsis	Unknown	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=HP_0100806
ischemic stroke	Phase 3	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_1060198
Cognitive impairment	Unknown	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=HP_0100543
Hypoxemia	Unknown	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=HP_0012418
Loss of consciousness	Unknown	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=HP_0007185
adrenocortical insufficiency	Unknown	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0000004
depressive disorder	Unknown	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0002050
head and neck neoplasm	Unknown	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0005586
hypertensive disorder	Phase 3	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0005044

1 to 10 of 16Source Open Targets

See all 16 diseases

Trials75

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 2 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT02643381	Etomidate Versus Ketamine for Emergency Endotracheal Intubation: a Prospective Randomized Clinical Trial	Phase 4	801	2021-12-15	etomidate	Its name	ClinicalTrials.gov
NCT03545503	Evaluating the Hemodynamic Effects of Ketamine Versus Etomidate During Rapid Sequence Intubation	Phase 4	428	2021-11-26	etomidate	Its name	ClinicalTrials.gov
NCT01823328	Ketamine Versus Etomidate for Rapid Sequence Intubation	Phase 4	143	2019-05-24	etomidate	Its name	ClinicalTrials.gov
NCT00441792	The Effect of Etomidate on Patient Outcomes After Single Bolus Doses		122	2012-04-06	etomidate	Its name	ClinicalTrials.gov
NCT03820388	Comparison of Etomidate Plus Propofol, Etomidate Alone on Induction of Anesthesia	Phase 4	75	2021-02-23	etomidate	Its name	ClinicalTrials.gov
NCT02027311	Etomidate vs. Midazolam for Sedation During ERCP	Phase 4	63	2015-06-29	etomidate	Its name	ClinicalTrials.gov
NCT00462644	Evaluation of Etomidate on Adrenal Function in Trauma Patients		30	2009-11-11	etomidate	Its name	ClinicalTrials.gov
NCT04934683	The GUARDIAN Trial - Induction Agent Sub-Study	Phase 4	6,254		etomidate	Its name	ClinicalTrials.gov
NCT01913054	Combined Use of Etomidate and Propofol in Painless Gastroscopy.	Phase 4	2,450		etomidate	Its name	ClinicalTrials.gov
NCT05277896	Randomized Trial of Sedative Choice for Intubation	Phase 4	2,367		etomidate	Its name	ClinicalTrials.gov

1 to 10 of 75

See all 75 trials

Comparisons in its trials15

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Etomidate vs Ketamine: Survival at Day 28	254 of 396	264 of 395	791	NCT02643381	Trial comparisons
Etomidate vs Ketamine: Number of Participants With New Diagnosis of Adrenal Insufficiency	11 of 396	4 of 395	791	NCT02643381	Trial comparisons
Etomidate vs Ketamine: Survival at Day 7	306 of 396	336 of 395	791	NCT02643381	Trial comparisons
Etomidate vs Ketamine: deaths from any cause	142 of 396	131 of 395	791	NCT02643381	Trial comparisons
Etomidate vs Ketamine: serious adverse events	10 of 396	9 of 395	791	NCT02643381	Trial comparisons
Etomidate vs Ketamine: deaths from any cause	0 of 194	0 of 204	398	NCT03545503	Trial comparisons
Etomidate vs Ketamine: serious adverse events	0 of 194	1 of 204	398	NCT03545503	Trial comparisons
Ketamine vs Etomidate: Mortality	8 of 62	15 of 67	129	NCT01823328	Trial comparisons
Ketamine vs Etomidate: Number of Patients With First-pass Success	59 of 62	60 of 67	129	NCT01823328	Trial comparisons
Ketamine vs Etomidate: serious adverse events	1 of 62	0 of 67	129	NCT01823328	Trial comparisons

1 to 10 of 15

See all 15 comparisons in its trials

Papers from its trials41

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
35226737	RESULT	1	PubMed
29715485	RESULT	1	PubMed
27646281	RESULT	1	PubMed
26871805	RESULT	1	PubMed
25535501	RESULT	1	PubMed
25478364	RESULT	1	PubMed
23399487	RESULT	1	PubMed
23188232	RESULT	1	PubMed
23114490	RESULT	1	PubMed
21563653	RESULT	1	PubMed

1 to 10 of 41

See all 41 papers from its trials

Tests in its trials3

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

Test	Trials naming it as an outcome	Source
Card Sorting Test (Berg)	1	ConductCognition
Clock Drawing Task	1	ConductCognition
Verbal Fluency	1	ConductCognition

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL681

GET https://conductscience.org/api/drugs/v1/CHEMBL681/trials?page=2

API reference For AI assistants